Compare BIO-TECHNE Corp (TECH) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Vanguard Total International Stock Index Fund ETF — how do they compare? BIO-TECHNE Corp trades at $71.63 (market cap $11.16B), while Vanguard Total International Stock Index Fund ETF trades at $84.5. The key difference: BIO-TECHNE Corp pays a 0.45% dividend while Vanguard Total International Stock Index Fund ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, Vanguard Total International Stock Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| TECH | VXUS | |
|---|---|---|
Market Cap | $11.16B | — |
Sector | Health | Sector/Thematic |
52-Week High | $72.12 | $87.06 |
52-Week Low | $43.31 | $68.24 |
Enterprise Value | $11.24B | — |
Dividend Yield | 0.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
VXUS trades at $83.07, down 0.36% with a bearish technical signal from moving averages. The ETF provides diversified international exposure across 8,700+ stocks in developed and emerging markets. Recent institutional buying includes Greenwood Gearhart increasing its position by 45.8% in Q1 2026 (SEC filing, July 20, 2026). Technical indicators show neutral oscillators with support at $82 and resistance at $84.
VXUS offers cost-effective international diversification at a 0.05% expense ratio, trading at a discount to US equities. Risks include global economic sensitivity and currency fluctuations. Analyst sentiment is mixed with some caution due to inflation concerns, but long-term value exists for investors seeking non-US exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
